N
Google TrendCOVENTRY VS NEWCASTLE (2000+) — Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:coventry vs newcastle2000+levante - sevilla2000+servicio de control de inmigración y aduanas1000+indigo girls200+afc champions league200+essie fall nail polish trends 2026200+geomagnetic storm aurora visibility northern us500+matthew stone sr500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Safety and reactogenicity" (30 stories)

Top Headline Story

Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial
Lead StoryThe Lancetworld
May 6

Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQN0h0YURaSkhma19GZnpIQ2V1SWRYMDNESW5nQkJUTHZCTUFXVVg3R3NIODJSYlVjZnZDS2hvdHRlQnFOMERMYmRkdGFxemtRZm5GTmRXV0hNR1duekZIVUxUUWZYSXhIUExnLU02OTJ1WG9aWWF2UklnbXppdmN0VEQ2MkZrRWMxdTM4?oc=5" target="_blank">Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+23m ago

coventry vs newcastle

Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats

Filter stories
2000+23m ago

levante - sevilla

Levante - Sevilla en directo

Filter stories
1000+23m ago

servicio de control de inmigración y aduanas

"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon

Filter stories
200+23m ago

indigo girls

Indigo Girls cancel show after tour bus driver dies in highway crash

Filter stories

Search Results for "Safety and reactogenicity"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis
Naturegeneral

Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vQ3FGOXNtMUtsWTlVS1VvM01sTHFQdWZxbThibXNpZnQzY0ZNdTF2dlZBVlRndzRkLWV0QzZrRV9IbTlOZlBoMlE3MC10UDFPMDU1U3QxZTJydlh6RkZj?oc=5" target="_blank">Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine
NEJMworld

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1GSTIwSFJ5WjRtNVJ2Vk1EOVNGekxLRnFWT2lGMFd0SXgyUlROdldJUlNwQWJMR2tjQ25RYlF5MzcySk9XQXZ6dEt4OTdQUmxTc09MbEJZZEQ4R1dkZXM4Rw?oc=5" target="_blank">Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
The how’s and what’s of vaccine reactogenicity - npj Vaccines
Naturegeneral

The how’s and what’s of vaccine reactogenicity - npj Vaccines

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTFBjUGZMV2VBRENiLTM0T3duWGZBc0dlNzlYZVlkVEVCVVQzbFdLbzBMSVNtZFlMclVFZjNTVGRlNm1ibmZrX1dIVFZSS1hjZy1QRm80Z1R0REhyWHBkMXc?oc=5" target="_blank">The how’s and what’s of vaccine reactogenicity - npj Vaccines</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase
The Lancetworld

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOTzN0NVdIZzg4WDRuWkFneUZtS2xmc0E2N3NDd2hEdDNrQkxWMGVNR3M5QU52c2JHNmY0Y1hpTzdqdktmNHRTdmtzS3p2Ql8wR1FxR2ZtMTNsbnNEQk9EMldiUllXNGZRR0hvbUZ4VE03NF9BUWFOZHFmd3gxSUp0b2k0TGw1RVQ3Umww?oc=5" target="_blank">Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
NEJMworld

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1IVWstZkpqYjdjOUlER2R1ZkxicFRyaHZXLUNIa1ZiYUQtY2ZGTnVCNV9McTktckV1ZnprQmhqU2Y2QWNxTjhCUTctX0l3RTV5Q2tVSnVFdHZFZjJyR1UtVw?oc=5" target="_blank">Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands | npj Digital Medicine
Naturegeneral

Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands | npj Digital Medicine

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE4wMUVhTzM3WFNDR0Y1VGJmTkZSRjZGRFA0TmlwQThlbGFfZmVVeEJjWGxIaGJkY180T3dMbFAtVmZkT0RzalVFLUlGWnpDdGItOHlVamFuQ1k5TE1JRjNz?oc=5" target="_blank">Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands | npj Digital Medicine</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
The Lancettech

Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOVThEZWxKcndoTGRHWEpRY09ZV0swLThFOGJkTG5zMFpUT0RzbFZlcm5kV01UZVhaZGU3NUlzdWVHcHViWlZGanJBSVgzZ2Z6UUNHYkQxRXFWcUlHTmk3M1lveTZQQWJxR0EzOFctc1RHWnRqdUhtcUZOR1dVdGRfTlJ2U3ZqM0ZpQXU0?oc=5" target="_blank">Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis
Naturescience

Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBId3dad1ZGRVVtLWx2RzNtYktxVVgzUUxfTUthNHBzRFRaU0tycFBzOHh6dlNHRGVSMFZ0dlloc2VkNFQ4enBYZmZQNTlMZWtNYjh5bFVldDYxZ2JYSnVJ?oc=5" target="_blank">Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
The Lancetscience

Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNZEFXaGpoek8xQ050cE5GS2s3eWtXSjE3VV9uMlphaGlraFB5WS12cFFTNXB2M1BvejRBaU91TUc4M2otWUluVDV2Z0R5WWFqd2VxajNhckw5OG9TZjNkTktONEdkM0xuQm1PdUdFc2s3Rm5rY195MndNeEVHTnUtTmR0SVFZSkZGRFZB?oc=5" target="_blank">Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines | Experimental & Molecular Medicine
Natureworld

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines | Experimental & Molecular Medicine

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5zeTZUQ3JqbG42QmtnZ1ZZc2xUYk1Eb0lsa0ZCWTN2U3RiaWJuVEtlZnd4Y1Vlc2pEZ2xHa3J4YU5JYlBaS2RSZmVpd1dOdUdHekFZV3FoaFUtOFZwR3lV?oc=5" target="_blank">Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines | Experimental & Molecular Medicine</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
The Lancetworld

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNV2t0X2EzUngyRzlXb0luek9TTUhiOXd1WDRiVEd4WmEwaEllSEZsOTlycjl3eWlLSV9lSlJnZE45dUlIODVhLXA5QUNSRldwcnVRU1dvR0tGbUt2elc5UUxTN0VjcjROc3pmdXh5d2FmdWZpQXNHbEVGcE1YVUtJRk01ejRkT3k2dWx3?oc=5" target="_blank">Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
Natureworld

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFA3SlZTTlNhc3J1RTJyZ0lIYmx1bkxISWpfeWp6MDJOckdTU2RBRGxyeFNRQm4zWGRyZU9UUmxBQkp0aXBtWkhPVWxJTU1FRTJwS095S2pSaU5FQmpGdnN3?oc=5" target="_blank">Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial
The Lancetworld

Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOVTlMNHBScXRfeV8xQ19sZ1FWM21TWUJKMmJpOUdnMlZ2aGl1Q0NMMEdraENTdVhlMW5saEVDLWFobW1fSDhpN29OdDUteGxsSktqQ3dXR05wbTd1YkZUcEx6d1lUb0hTNHdEeXNVVHJYM2JMQkU5TEFsRXFFUHNyeWd5Y3VPcGJDZ0hz?oc=5" target="_blank">Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactions
Natureworld

A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactions

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE8tQ1AwdnJ0dXBROENaa3RZRWFaNUNZQUZKQzlFUktyRXNuek9sbnN6eDZUaXRFN0FEdFJEUHIzREpZR3hRNWRkc0lMc182eTl2Q1ZBVHZmTk5SVm1FcTl3?oc=5" target="_blank">A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactions</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
The Lancetworld

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQa2lOMlZfc2dTRUF1VUN5V0NBaTV5WE1jNENWbG5HUnU0UFVONjZ4b2h5ZkJHN3laQ2VQVmxZX3NseHZBd0w1S2I4UjdLMkNvOU1CTTRMUk9XLUJVTVVQYjFSQzZ6TWlJTmFja0Utc3dQRFM0R1dzakR6UnV3YjZNMWRJRkwxRGRNa3FF?oc=5" target="_blank">Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials
Natureworld

Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE56TVJSWDMteFN6OUloRkxaeFdXSFRycW5ZSWhibXB1Vi1JM1JRWkJwSmxaRDQyUW1aYjNqMUV2RTY4QmZHUEV6U29hcDJBUndqaDdKSHZ6R0VlTHhjanVv?oc=5" target="_blank">Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial
The Lancetworld

Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNR2w1dGlFeU5KRzYyWU01djA2UmZLaklsREh6R1VQeG0xTmRMNUFaUWVvem1fenBKX05hR05WYnpVWmlpSW1BeE52ald6NEpZNWRsVGtYdW0xYkRmemNFZmpCNVc5dUFlVkJBbjlaY1lKRk9hMEpkbk1xdmM2VmpFYWhvRkxEaXlzbjVF?oc=5" target="_blank">Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase
Natureworld

Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE15d2MzbnlhdG82NEFjSm9kTlc5LTk2U2xaUFYzU2dPdEVnbzNtamZhUExfekNmTWRmam5zSUd3Yy0yMW5Ja3hLUEhJblBCVDlTVW50c2xXYXptaUc4QlVF?oc=5" target="_blank">Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
Naturescience

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE90ZnVzZnhHdGlOZkxIV2tYR3pOSFZzb1lCSDdjVXZubW9HSjl5a01QOTRjRGtEY2JfUDJmcmxWeEQ0X05fanBheXJRTWNDUDUtQVR5ZElJZ1pIZk9aTGpn?oc=5" target="_blank">Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
The New England Journal of Medicineworld

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBMcHVrUms0VXRHRnJqcDBUUjhDNmIzT1NDN3dRb0ZxTXpWUDRubkNZMXVGdGlJclVTbmprRHgwM3g2cHp2akFPdzRlOU04X3VQeXhsOU80aV9URlVBUzlVSA?oc=5" target="_blank">Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate</a>  <font color="#6f6f6f">The New England Journal of Medicine</font>

Read Full StoryMore like this
Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium
Naturegeneral

Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB2UzRFMGxyRm1jZk45bEgwTGVNOXB1ZFRfaUdOVDlYNFNjR2x4MXJfczFDb0FkN3hkUUV2OVBFNzFQX1ViWWlLMGJXNFMzTVJJZ2dhWDJIbEhoaTdtRXVZ?oc=5" target="_blank">Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
The Lancetworld

Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPSmJPRWhxV0xzQWROWldsa092WE1ESWdsVXBoTTRoeEZudVp4alNSc1JHRjhhLTM1bjNKWG5TQTRha2ZUTTZHT3FSekxqaFhkMkFWSmNVeV9XYXd6WWQ4QWc4eWNzOHZscDczQlBpbWZBM1hnOHhDWF9lNHJPdTVRUjNORm5CaGtpUUMw?oc=5" target="_blank">Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
The Lancetgeneral

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNbkZTNUNoYTJkUmN2VmxiY1MyY3hlQUU3VGdUMElpRjg3aGllVGtvaXByWFljSG9sOG9TdmM3Y2NJaDc4OGcxaEZrWUE5WXhjekNqb2ZVRFVaVDBhVy0zZTlWMTdSOW5PVnhiZWlEM3RONFVoVWZoSzIzYlh2UDZjbkdQMkw2VE5n?oc=5" target="_blank">Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
The Lancetworld

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTDRTcHllUXhVUXBjbG42OW54ZEZ0VVBRcGZ5Vmp5WUU5QlBVeC11MTRWVHRqSG9VNjBXUEU1VnM0U0RLSXUtWG13SXBZVnJmSmxvSEtmdURjYS1NS193UC1CSFd6NHV0ang0NTczRWxsNmtCdUVOUHo5TEZxY0ZMY09Nel9Samlq?oc=5" target="_blank">Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI | npj Vaccines
Naturegeneral

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI | npj Vaccines

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE16eHRmSnV2YkdwM0xQUkpmZU5ybGRGYnBfc1lyd01fMWVxQzJVWW5sX2hqNkdlVnFpdG5FcnJVSXR0Y2ppLThCUVZMUm1Vd3VIcS1sMXdyUGFiUWF0WDhj?oc=5" target="_blank">A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI | npj Vaccines</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Vaccine MVA-BN shows consistent, robust immunogenicity and safety results
News-Medicalworld

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQVEQ5N0l5Z1lnX2VGUzNOeGZMUGptaUFnZmZMTXdwYm03VzYyQmU3dGNpSXE2eE5MZlFJR2lVQkxVbm5hdEs1dWdnZkE4V3R3YU5MQXBvemp2ajlDZDg3SVUzNDBUWTVMc2ZVcTRaQnV3bkQ1WGh3eTh3Q2VDaEY2T3pFYmZJQ3N4Y2JFSkxxUzF2bTVUMlhxSE90SkhEMUhHekc0bjlfdlNmTUpNem9HeU11Z2tvNnBCSl8xVw?oc=5" target="_blank">Vaccine MVA-BN shows consistent, robust immunogenicity and safety results</a>  <font color="#6f6f6f">News-Medical</font>

Read Full StoryMore like this
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
NEJMgeneral

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBQdjZBMGo5YVljZXFBSlQyRUxFMGJPSlRXSGsweU55LUpmRFQyLWc4bTdtaS1Ob2dBQmN2WkR1aklIWVgxSW1yekRJTGpBcWRvVjRVS3BHN2dxX1FhTG5GWQ?oc=5" target="_blank">Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Novavax’s COVID-Influenza Combination Vaccine Demonstrates Reassuring Preliminary Safety Profile
Pharmacy Timesgeneral

Novavax’s COVID-Influenza Combination Vaccine Demonstrates Reassuring Preliminary Safety Profile

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOS2FvUzE5RVJjNHJiY2E1a1N6ajRUbjRvTnhDMExOWUNZSjJ6UjZ4THBGUW93dXVaT0E3eHhSbVpRMGVDOC1jMi1sbUdDeTNnWE1pWVNJQUVkVFB6Zkl6VGpuLWJDWUpJVkZ5Sm1zaFItc05WZS00MG0ybkgtb3FPby13UFZGMFFoNVZ5NnlBY0lfRzh4cXM0aEhhM1l6dHVqNm14ZExTV1I3LUdScTUwaHN1cG44aHRWYmtPTUpYTGhXM1NYdTh6U2JSTQ?oc=5" target="_blank">Novavax’s COVID-Influenza Combination Vaccine Demonstrates Reassuring Preliminary Safety Profile</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
NEJMtech

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBrQjVlUUwwbElzMHhVWTF2dTd3N2NDV19FVUhocHh2QXg0Rk44S0ZaOWRiUXExdEF1bUgzc3I4YkxHcGtqNXZ5RDd4LWRUQU52aVdtWXdhVXNMQ2JMOFJJRw?oc=5" target="_blank">A Bivalent Omicron-Containing Booster Vaccine against Covid-19</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
"Safety and reactogenicity" — Live Google News Trends & Headlines